• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Acceleron Pharma appoints Thomas McCourt to its board of directors

Acceleron Pharma appoints Thomas McCourt to its board of directors

July 26, 2016
CenterWatch Staff

Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, has announced the appointment of the experienced commercial executive, Thomas McCourt, to its board of directors, effective immediately.

"We are pleased to welcome Thomas McCourt to our board of directors. Tom’s expertise in designing and implementing commercial strategy, building sales and marketing organizations and launching several important therapeutics, will be invaluable as Acceleron prepares for the next stage of corporate growth," said Francois Nader, M.D., chairman of Acceleron’s board of directors.

McCourt serves as chief commercial officer and senior vice president of marketing and sales of Ironwood Pharmaceuticals. McCourt brings 30 years of experience building commercial strategies and capabilities across multiple companies for new therapies. Prior to joining Ironwood in 2009, where he led the commercial launch of Linzess, McCourt led the U.S. brand team for denosumab at Amgen. Before that, he held a number of senior commercial roles with Novartis, including directing the launch and growth of Zelnorm for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation. He was also vice president of strategic marketing and operations during his tenure at Novartis.

Earlier in his career, McCourt was part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and serving as brand manager for Prilosec. He earned a degree in pharmacy from the University of Wisconsin, where he serves as a member of the board of visitors for the School of Pharmacy.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing